Incyte licenses Hengrui's anti-PD-1 mAb

Incyte Corp. (NASDAQ:INCY) acquired exclusive, worldwide rights outside of Greater China to SHR-1210, a mAb against PD-1 from Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:3600276).

Hengrui will receive $25 million up front and is eligible for $90 million in regulatory milestones, $530 million in commercial milestones, and $150 million "based on clinical superiority" of the compound, as well as double-digit royalties. Incyte will be responsible for all development and commercialization costs outside China, Hong Kong, Macau and Taiwan. ...